BLTE logo

BELITE BIO INC - ADR

BLTENASDAQ
🏆 #1115 by market capEarnings Nov 9US Equity
$910.50▼ $66.83 (−7.34%)
Simulated price
🔔
Track BLTE
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.3%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$6.65B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for BLTE.

Trading Snapshot

Day Range
$899.43 – $918.07
52-Week Range
$70.17 – $200.00
Volume
$2.13B
Avg Volume
$2.40B
Shares Outstanding
40.1M
Next Earnings
Dec 4, 2026

Fundamentals Snapshot

Annual Revenue
$573M
Last Q Revenue
$131M
P/E Ratio
-60.1
P/S Ratio
0.0x
EPS (TTM)
$-2.55
Dividend Yield
0.00%
Dilution (1yr)
+6.6%

Why Investors Own BLTE

  • ✓High-growth profile — revenue up +46.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BLTE logo

BELITE BIO INC - ADR

BLTE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$84M▲ +110.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$37M▲ +26.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
33.5M▲ +6.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$353M▲ +$321M YoY
StockOtter · stockotter.space

About BELITE BIO INC - ADR

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$1,091.49
▲ +19.9% Upside
High Target$1,325.59
Low Target$947.96
Based on 16 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

BELITE BIO INC - ADR tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift BLTE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

BELITE BIO INC - ADR announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.